Evaluation of Adherence Rate in Patients Receiving PegIntron [peginterferon alfa-2b]/ Rebetol [ribavirin] (Weight Based) for Hepatitis C in Conjunction With a Patient Assistance Program

Trial Profile

Evaluation of Adherence Rate in Patients Receiving PegIntron [peginterferon alfa-2b]/ Rebetol [ribavirin] (Weight Based) for Hepatitis C in Conjunction With a Patient Assistance Program

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2014

At a glance

  • Drugs Peginterferon alfa-2b/ribavirin (Primary) ; Antidepressants; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 19 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top